Click to edit Master title style0

1

COMBINED GENERAL MEETING

22 June 2016

Bacteria’s natural predator

Click to edit Master title style0

2

Disclaimer/

When receiving this presentation or participating in this meeting, you acknowledge having taken note of the following restrictions.The present document and the information contained in the presentation are strictly confidential. This document cannot be copied, reproduced, distributed, published or otherwise disclosed, directly or indirectly, in whole or in part, to any other person (within or outside your company). In particular, neither this document, nor any part or copy thereof can be distributed, directly or indirectly in the United States, Canada, Australia or Japan. Non-compliance with these restrictions can lead to a violation of legal restrictions in certain countries.This presentation neither constitutes, nor is it a part of, and should not be construed as an offer of subscription to securities or a solicitation for subscription to securities in France, the United States or any other country. Securities may be offered or sold in the United States solely following registration pursuant to the 1993 U.S. Securities Act, as amended, (hereinafter: the “Securities Act”) or in the case of an exemption from this obligation to register. This presentation is not a prospectus. No offer to the public of financial instruments will be made in France before the approval of the prospectus (the “Prospectus”) by the Authority regulating financial markets in line with the provisions set out in Directive 2003/71/CE. Any decision to acquire financial instruments must be made solely on the basis of the information contained in the Prospectus. No offer to the public of financial instruments will be made in any jurisdiction, except in France. In particular, no financial instrument will be registered in line with the Securities Act, or with any authority for any of the States or jurisdictions in the United States.This presentation only contains summary information and it is in no case an exhaustive presentation. The information contained in this document, whether from internal or external sources, is presented solely on an indicative basis, and it has no contractual value. The information contained in this presentation is up to date on the day of the presentation. Portions of the information contained in this presentation and other declarations or documents, published or to be published by Amoeba (the “Company”) are not factual elements but prospective statements. These statements are based on opinions, expectations and hypotheses, including statements relating to the Company’s current and future commercial strategy, or those relating to the distribution environment in which the Company operates, and harbors known and unknown risks, uncertainties or other factors. The Company’s results, performances or creations, the sector results or any other event could be significantly modified relative to the projections expressly or indirectly described in this presentation. The Company, Bryan, Garnier & Co and Portzamparc have not provided any declaration or either explicit or implicit guarantee as to the accuracy, genuineness, exhaustiveness or relevance of the information and opinions contained in the present document. The Company’s responsibility and that of Bryan, Garnier & Co and Portzamparc cannot be engaged (in particular for reasons of negligence) for any prejudice resulting from any use of this presentation or its contents, or linked in any way to this presentation. This information can be subject at any time to modifications, including and not limited to, due to changes to the applicable regulations or market conditions. The Company, Bryan, Garnier & Co, or Portzamparc are not, and cannot be, under any obligation to update this information. In the hypothetical situation where an offer of financial instruments is made by the Company in the future, investors must found their decision to invest solely on the basis of (i) the Prospectus or any other similar document which must be prepared by the Company as part of the offer, and in particular the risk factors described therein, (ii) any notification published by the Company modifying the terms of the offer, and (iii) any examination of the Company considered necessary by a potential investor. You must not accord excessive significance to the information contained in this presentation in terms of its genuineness, exhaustiveness, accuracy or relevance. It is the responsibility of each potential investor, if an offer of financial instruments is made in the future, to carefully examine the Prospectus and independently assess the risks and advantages of the offer.Market data and some sector forecasts included in this presentation were obtained from internal surveys, estimations, reports and relevant studies, as well as from market studies, publications or publicly available information. The latter were not the subject of independent verification by the Company, Bryan, Garnier & Co or Portzamparc, or their respective subsidiaries, social agents, directors, advisers or employees. The Company, Bryan, Garnier & Co, and Portzamparc do not declare or either explicitly or implicitly guarantee the accuracy, genuineness, exhaustiveness or relevance of the information contained in the present document.

Agenda

1. Constitution of the General Meeting

2. Activity Report

3. Report of the Supervisory Board

4. Report of the Statutory Auditors

5. Q&A

6. Vote on the resolutions

Agenda

1. Constitution of the General meeting Committee

2. Activity Report

3. Report of the Supervisory Board

4. Report of the Statutory Auditors

5. Q&A

6. Vote on the resolutions

Click to edit Master title style0 Key events in 20152

A successful IPO

5

* Eligible for inclusion in the long-only SRD, Deferred Settlement Service

07-2015 31-12-2015

IPO: Compartment C* €8.3 /share €34.6/share

Raised €13.2 M

of which individuals €2.8 M

Number of shares (not diluted) 5,358,157

Number of shares (diluted) 5,922,157

of which in the free float 1,126,159

Market capitalization €44.5 M €185.4 M

Click to edit Master title style0 Key events in 2015

Building a distribution network

6

2

Market awarded

Market currently

negotiated

Click to edit Master title style0 Key events in 20152

Further industrial tests in a real environment

7

BeginningDuration (months)

Focus / Request / Comment

Oct-15 Ongoing Substitution for chemical biocides

Oct-15 4Substitution for chemical biocides

August-14 OngoingSubstitution for chemical biocides

July-15 3 Substitution for chemical biocide on tertiary sector ACT

March-15 5 Substitution for chemical biocides

Oct-14 6 Biofilm and total bacteria

August-14 Ongoing Reduction of chloroform emissions

April-14 5 Water consumption and corrosion

Nov-13 Ongoing Corrosion and preventive test on new ACT

June-13 20 Substitution for chemical biocides

Chemical Industry

Aerospace research

Automotive manufacturer

Pharmaceutical industry

Food industry

Aeronautical sector

Click to edit Master title style0 Key events in 20152

End of assembly for European production lines

8

Modular 500 L production lines

Prototype

Laboratory pilot& Industrial pilot

Industrial production validated in a 500-L reactor

Construction of the first production line

2 Operational 2x 500 L production lines

Click to edit Master title style0 Key events in 20152

The regulatory procedure is under way in Europe

9Phase II –Pilot industrial tests

Temporary MA France

Phase III – Industrial tests with R&D MA

Final MA UE

Click to edit Master title style0 Financial results and key indicators2

Group P&L Account (IFRS standards)

10

In K€ 31/12/2015Audited

12 months

31/12/2014Audited

12 months

31/12/2013Audited

12 months

Operating revenue

590 551 424

Operating costs (4,578) (1,474) (918)

Operating income

(3,988) (923) (493)

Financial income (31) (52) (27)

Net income (4,019) (975) (521)

Click to edit Master title style0 Financial results and key indicators2

Group Balance Sheet (IFRS standards)

11

Liabilities in K€

Equity 10,599 2,799 434

Non-current liabilities

1,797 1,403 656

Current liabilities

1,739 1,348 1,145

Total Liabilities 14,135 5,551 2,235

Assets in K€ 31/12/2015Audited

31/12/2014Audited

31/12/2013Audited

Non-current assets

4,801 2,412 1,617

Current assets 9,334 3,139 619

Total Assets 14,135 5,551 2,235

Click to edit Master title style0 Financial results and key indicators2

Cash Flow Statement

12

in K€ 31/12/2015Audited

31/12/2014Audited

31/12/2013Audited

Operational activities (4,165) (1,193) 500

Investment activities (2,442) (893) (529)

Financing activities 11,720 4,244 122

Change in cash 5,113 2,158 93

Closing cash 7,731 2,618 461

Click to edit Master title style0 Next Steps2

13

Couverture commerciale: objectif *

201720162015

** Each horizontal line corresponds to one operational production line

Magnus (Canada)

Earthwise (United States)

Aquaprox (France)

New American distributors

New European distributors

* Each horizontal line corresponds to an individual distributor

Novochem (Benelux)

DREWO (Italy)

Aqua Concept (Germany)

Aqua Concept Polska (Poland)

Green Chemicals (Turkey)

France

Rest of Europe

USA

Commercialisation following MA

Europe: 2 units of 4 reactors (end of 2016)

USA: 2 units (end of 2017)

Industrial: Number of operational production units**

Canada: 1 unit of 4 X 10 Litre (mid 2016)

Commercial coverage: objectives *

** Each horizontal line corresponds to one operational production line

Click to edit Master title style0

14

Next steps2

Temporary MA

France & EuropeOperational

Production lines

Today

Economic model to be ’pasted’

Where we are headed

S2 2016

Cooling

towers

Nuclear

power plant

Domestic

hot water

Drinking water

network

Food & agriculture

sector

Veterinary

industry

€1.7b €1.7b €6b €10b €0.5b €0.5b

2016

2017/2018 2019/2020

Agenda

1. Constitution of the General Meeting

2. Activity Report

3. Report of the Supervisory Board

4. Report of the Statutory Auditors

5. Q&A

6. Vote on the resolutions

Agenda

1. Constitution of the General Meeting

2. Activity Report

3. Report of the Supervisory Board

4. Report of the Statutary Auditors

5. Q&A

6. Vote on the resolutions

Agenda

1. Constitution of the General Meeting

2. Activity Report

3. Report of the Supervisory Board

4. Report of the Statutory Auditors

5. Q&A

6. Vote on the resolutions

Agenda

1. Constitution of the General Meeting

2. Activity Report

3. Report of the Supervisory Board

4. Report of the Statutory Auditors

5. Q&A

6. Vote on the resolutions

Click to edit Master title style0

19